Furthermore, it is noteworthy that SGLT-2 inhibitors demonstrated a higher efficacy in reducing HHF when compared to GLP-1 receptor agonists in patients with type 2 diabetes [38]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.